- BRAF mutations represent a highly heterogeneous group of molecular alterations seen in colorectal cancer (CRC).
- Class I BRAF mutation (V600) render aggressive biology to CRC and poor response to EGFR blockade therapy.
- Currently there are limited data on clinical and molecular features of class II and III BRAF mutations and their response to EGFR blockade therapy.
- In this study, we investigated the clinical and molecular characteristics of BRAF mutation classes and their impact on clinical outcomes in a large cohort of patients with mismatch proficient-microsatellite stable CRC.
Publications
Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC
– Caris Life Sciences